Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 268,932 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total value of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.41, for a total value of $47,738.99.

Hims & Hers Health Trading Down 7.0 %

NYSE:HIMS opened at $25.74 on Friday. The stock has a market capitalization of $5.62 billion, a PE ratio of 58.50 and a beta of 1.31. Hims & Hers Health, Inc. has a 1-year low of $8.14 and a 1-year high of $35.02. The firm has a fifty day simple moving average of $27.11 and a 200 day simple moving average of $21.62.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.04) EPS. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HIMS. Piper Sandler boosted their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday. They issued a “buy” rating and a $35.00 price target on the stock. Finally, TD Cowen restated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $24.80.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its stake in shares of Hims & Hers Health by 763.4% during the 2nd quarter. Principal Financial Group Inc. now owns 143,793 shares of the company’s stock worth $2,903,000 after acquiring an additional 127,138 shares during the period. Commonwealth Equity Services LLC acquired a new stake in Hims & Hers Health during the 2nd quarter valued at $479,000. Van ECK Associates Corp bought a new position in Hims & Hers Health during the second quarter worth $111,000. Rhumbline Advisers increased its holdings in shares of Hims & Hers Health by 50.1% in the second quarter. Rhumbline Advisers now owns 268,420 shares of the company’s stock valued at $5,419,000 after purchasing an additional 89,535 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after purchasing an additional 1,212 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.